Articles tagged "Immunosuppression"

2019 American Transplant Congress
Patient Centered AUC-Monitoring of Tacrolimus Using Capillary Microsampling
M. T. Gustavsen, K. Midtvedt, N. Vethe, S. Bergan, A. Åsberg
Oslo University Hospital, Rikshospitalet, Oslo, Norway
*Purpose: To reduce unwanted side effects of Tacrolimus (Tac), improvement of dosing is warranted. Therapeutic drug monitoring (TDM) of Tac based on trough concentrations (C0)…
2019 American Transplant Congress
Soluble C Type Lectin Receptor Protein Inhibition of Natural Killer Cell Mediated Tubular Epithelial Cell Death
S. Balaji¹, B. Fuhrmann², D. Lian³, H. Diao³, S. Ma³, Z. Zhang³, A. M. Jevnikar³
¹Physiology, Western University, London, ON, Canada, ²Microbiology and Immunology, Western University, London, ON, Canada, ³London Health Sciences Centre, London, ON, Canada
*Purpose: We have previously shown that Natural Killer (NK) cells can mediate kidney tubular epithelial cell (TEC) death and kidney ischemia-reperfusion injury (IRI) as well…
2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…
2019 American Transplant Congress
Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients
M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Sub-therapeutic tacrolimus trough levels have been associated with increased risk of rejection in renal transplant recipients and supra-therapeutic levels with infectious risks and drug…
2019 American Transplant Congress
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber
Methodist Hospital, Houston, TX
*Purpose: We have previously shown that despite the use of T cell-depleting antibody induction, AA kidney transplant recipients (KTR) remain at high risk of rejection…
2019 American Transplant Congress
Transplantation Alone Induces Myeloid-Derived Suppressor Cells Which Can Suppress T Cell Responses
Y. Lee, T. Zhang, J. S. Bromberg, J. R. Scalea
University of Maryland, Baltimore, MD
*Purpose: Myeloid-derived suppressor cells (MDSC) are a naturally occurring, heterogeneous population of highly immunosuppressive CD11b+GR-1+ cells that expand in response to inflammatory conditions. MDSCs develop…
2019 American Transplant Congress
A Cost Saving Quality Improvement Project in Solid Organ Transplant Population Following Tacrolimus Switch from Prograf® to Adoport® Immunosuppression – A Single Centre Experience
L. Mulreid, M. Vincent, L. Laycock, A. Summers, S. Bhutani
Manchester Royal Infirmary, Manchester, United Kingdom
*Purpose: Tacrolimus is widely used immunosuppressive drugs in transplantation. The use of generic medications is cost saving and economically advantageous for the National Health Services…
2019 American Transplant Congress
Time to First Therapeutic Tacrolimus Trough in Kidney Transplant Recipients: A Comparison of a Weight Based versus a Non-Weight Based Dosing Strategy
M. Chunduru, K. Schnelle, S. Zhao, L. Wei, R. Daloul
Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Reaching a therapeutic tacrolimus (TAC) trough early post-kidney transplant is important in minimizing the risk of acute rejection. The aim of this study was…
2019 American Transplant Congress
A Multicenter Study Of mTOR Inhibitor Use In Intestine And Multivisceral Transplantation
M. C. Segovia¹, A. Mavis¹, J. Boike², Y. Patel¹, T. Schiano³, S. Jafri⁴
¹Duke, Durham, NC, ²NWU, Chicago, IL, ³Mt Sinai, NY, NY, ⁴Henry Ford, Detroit, MI
*Purpose: Review the frequency, indications and outcomes of the use of mTOR inhibitors (mTOR) after intestine (IT) and multivisceral transplantation (MVT) at multiple centers in…
2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…